AU2018385697B2 - Stabilized peptide-mediated targeted protein degradation - Google Patents

Stabilized peptide-mediated targeted protein degradation Download PDF

Info

Publication number
AU2018385697B2
AU2018385697B2 AU2018385697A AU2018385697A AU2018385697B2 AU 2018385697 B2 AU2018385697 B2 AU 2018385697B2 AU 2018385697 A AU2018385697 A AU 2018385697A AU 2018385697 A AU2018385697 A AU 2018385697A AU 2018385697 B2 AU2018385697 B2 AU 2018385697B2
Authority
AU
Australia
Prior art keywords
peptide
protein
seq
degron
chimera
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018385697A
Other languages
English (en)
Other versions
AU2018385697A1 (en
Inventor
Gregory H. Bird
James E. Bradner
Henry D. HERCE
Ann Maurine MORGAN
Rida MOURTADA
Loren D. Walensky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2018385697A1 publication Critical patent/AU2018385697A1/en
Application granted granted Critical
Publication of AU2018385697B2 publication Critical patent/AU2018385697B2/en
Priority to AU2024200512A priority Critical patent/AU2024200512B2/en
Priority to AU2026201801A priority patent/AU2026201801A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2018385697A 2017-12-15 2018-12-14 Stabilized peptide-mediated targeted protein degradation Active AU2018385697B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024200512A AU2024200512B2 (en) 2017-12-15 2024-01-29 Stabilized peptide-mediated targeted protein degradation
AU2026201801A AU2026201801A1 (en) 2017-12-15 2026-03-10 Stabilized Peptide-Mediated Targeted Protein Degradation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599608P 2017-12-15 2017-12-15
US62/599,608 2017-12-15
PCT/US2018/065784 WO2019118893A1 (en) 2017-12-15 2018-12-14 Stabilized peptide-mediated targeted protein degradation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200512A Division AU2024200512B2 (en) 2017-12-15 2024-01-29 Stabilized peptide-mediated targeted protein degradation

Publications (2)

Publication Number Publication Date
AU2018385697A1 AU2018385697A1 (en) 2020-04-30
AU2018385697B2 true AU2018385697B2 (en) 2023-11-09

Family

ID=65201672

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018385697A Active AU2018385697B2 (en) 2017-12-15 2018-12-14 Stabilized peptide-mediated targeted protein degradation
AU2024200512A Active AU2024200512B2 (en) 2017-12-15 2024-01-29 Stabilized peptide-mediated targeted protein degradation
AU2026201801A Pending AU2026201801A1 (en) 2017-12-15 2026-03-10 Stabilized Peptide-Mediated Targeted Protein Degradation

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2024200512A Active AU2024200512B2 (en) 2017-12-15 2024-01-29 Stabilized peptide-mediated targeted protein degradation
AU2026201801A Pending AU2026201801A1 (en) 2017-12-15 2026-03-10 Stabilized Peptide-Mediated Targeted Protein Degradation

Country Status (7)

Country Link
US (2) US20200354413A1 (cg-RX-API-DMAC10.html)
EP (1) EP3724216A1 (cg-RX-API-DMAC10.html)
JP (3) JP2021506814A (cg-RX-API-DMAC10.html)
CN (2) CN120118207A (cg-RX-API-DMAC10.html)
AU (3) AU2018385697B2 (cg-RX-API-DMAC10.html)
CA (1) CA3078682A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019118893A1 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120118207A (zh) * 2017-12-15 2025-06-10 丹娜-法伯癌症研究院有限公司 稳定肽-介导的靶向蛋白降解
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
KR102947433B1 (ko) 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
CN111393519B (zh) * 2019-11-21 2022-11-08 中国药科大学 作为krasg12c/sos1抑制剂的新型订书肽及其用途
WO2021141662A1 (en) * 2020-01-10 2021-07-15 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
AU2021262752A1 (en) * 2020-04-27 2022-10-13 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and HDMX-selective p53 peptides and uses thereof
US20220025341A1 (en) * 2020-05-29 2022-01-27 Massachusetts Institute Of Technology Minimal peptide fusions for targeted intracellular protein degradation
AR122707A1 (es) * 2020-06-23 2022-09-28 Genentech Inc Compuestos macrocíclicos y métodos de uso de los mismos
WO2022047734A1 (zh) * 2020-09-04 2022-03-10 孔二艳 将gfap氨基酸位点作为神经退行性疾病治疗靶标的应用
WO2022081827A1 (en) 2020-10-14 2022-04-21 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
GB202018608D0 (en) * 2020-11-26 2021-01-13 Zentraza Ltd Adhesive peptides
WO2022129621A1 (en) * 2020-12-18 2022-06-23 John Innes Centre Methods for targeted protein degradation
WO2022194087A1 (en) * 2021-03-16 2022-09-22 Cullgen (Shanghai) , Inc. Modified proteins and protein binders
CN113845598B (zh) * 2021-09-18 2023-06-30 中国人民解放军海军军医大学 一种蛋白质靶向嵌合体降解mdm2/mdmx蛋白的订书肽缀合物及其用途
US20230257725A1 (en) * 2021-10-22 2023-08-17 Massachusetts Institute Of Technology Minimal Peptide Fusions for Targeted Intracellular Degradation of FOXP3
EP4476268A4 (en) * 2022-02-07 2026-04-15 Ubiquitx BETA-CATENIN PROTEIN DEGRADATION
WO2023203127A1 (en) 2022-04-20 2023-10-26 Vib Vzw Alphabody-based degrader molecules
WO2023225625A2 (en) * 2022-05-19 2023-11-23 The Scripps Research Institute Bifunctional degraders comprising electrophilic protacs that engage dcaf1 and pharmaceutical compositions comprising the same
WO2024130217A1 (en) * 2022-12-15 2024-06-20 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
CN121443627A (zh) * 2023-05-05 2026-01-30 森迪生物科学公司 经修饰的降解决定子多肽和其用途
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 3-苯基丙基胺衍生物
CN117904060B (zh) * 2023-12-21 2024-09-24 上海大学 一种基于parkin的靶向蛋白泛素化降解剂及其制备方法和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
EP0958305B1 (en) 1996-07-05 2008-06-04 Cancer Research Technology Limited Inhibitions of the interaction between p53 and mdm2
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
ES2211033T3 (es) 1998-01-07 2004-07-01 Debio Recherche Pharmaceutique S.A. Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos.
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
BR0001870B1 (pt) 2000-05-29 2014-02-25 Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN109627287A (zh) 2007-02-23 2019-04-16 爱勒让治疗公司 三唑大环系统
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
JP2011522796A (ja) 2008-05-06 2011-08-04 ニューヨーク ブラッド センター, インコーポレイテッド 抗ウイルス細胞透過性ペプチド
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
US8524653B2 (en) 2008-09-22 2013-09-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010060112A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
EP2376100B1 (en) 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3698811A1 (en) 2009-06-18 2020-08-26 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
WO2011008260A2 (en) * 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US9227995B2 (en) 2010-04-23 2016-01-05 Øyvind Jacobsen Peptides
US9297017B2 (en) 2010-06-08 2016-03-29 University Of Washington Methods and compositions for targeted protein degradation
EP2588129A4 (en) 2010-06-30 2014-07-09 Univ Brandeis ON SMALL MOLECULES TARGETED PROTEIN REMOVAL
AU2011274474B2 (en) 2010-07-09 2015-06-18 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
EP2637680B1 (en) 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Cancer therapies
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS
US8762795B2 (en) 2010-12-17 2014-06-24 Microsoft Corporation Alerting recipients to errors occurring when accessing external services
SG10201601840RA (en) 2011-09-09 2016-04-28 Agency Science Tech & Res P53 activating peptides
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9346868B2 (en) 2011-11-14 2016-05-24 Carlos Witte-Hoffmann BLID; a novel protein domain for interaction with the Bcl-2 family of proteins. Applications in oncology
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2013116829A1 (en) 2012-02-03 2013-08-08 The Trustees Of Princeton University Novel engineered potent cytotoxic stapled bh3 peptides
KR102112373B1 (ko) * 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
US9556229B2 (en) 2012-05-18 2017-01-31 The Regents Of The University Of California Modification of peptides using a bis(thioether)arylbridge approach
CA3113959A1 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
WO2014053881A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
KR101616603B1 (ko) 2012-10-11 2016-04-28 서울대학교산학협력단 메틸 데그론 펩타이드 및 이를 이용한 단백질 수명 조절 방법
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
CA2894202A1 (en) 2012-12-18 2014-06-26 The Secretary Of State For Health Antimicrobial compounds, their synthesis and applications thereof
US9493510B2 (en) 2013-01-10 2016-11-15 Noliva Therapeutics Llc Peptidomimetic compounds
US9115184B2 (en) 2013-03-01 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Light-inducible system for regulating protein stability
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
CN111218447B (zh) 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10682388B2 (en) 2014-01-15 2020-06-16 The Board Of Regents Of The University Of Texas System Targeting of PELP1 in cancer therapy
US10040780B2 (en) 2014-03-03 2018-08-07 The Regents Of The University Of California Mcl-1 antagonists
WO2015175642A2 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
CN114805527A (zh) 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
JP2017538427A (ja) 2014-12-18 2017-12-28 インテグレイテッド ディーエヌエイ テクノロジーズ インコーポレイテッド Crispr系組成物及び使用方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
AU2016211517B2 (en) 2015-01-28 2021-05-13 Caribou Biosciences, Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10464975B2 (en) 2015-07-02 2019-11-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
EP3337476A4 (en) * 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US20190002506A1 (en) * 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
JP7049989B2 (ja) * 2015-08-28 2022-04-07 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Bfl-1と結合するペプチド
CN109069578A (zh) 2016-02-29 2018-12-21 达纳-法伯癌症研究所股份有限公司 用于治疗感染的钉合的细胞内靶向抗微生物肽
US20190076504A1 (en) 2016-03-23 2019-03-14 Dana-Farber Cancer Institute, Inc. COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
CN109152843A (zh) * 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN120118207A (zh) * 2017-12-15 2025-06-10 丹娜-法伯癌症研究院有限公司 稳定肽-介导的靶向蛋白降解

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CROMM, P. M. et al, "Targeted Protein Degradation: from Chemical Biology to Drug Discovery", Cell Chemical Biology, September 2017, vol. 24, no. 9, pages 1181-1190 *
NEKLESA, T. K. et al, "Targeted protein degradation by PROTACs", Pharmacology and Therapeutics, February 2017, vol. 174, pages 138-144 *
RICHARDSON, S. et al, 254th National Meeting and Exposition of the American Chemical Society, 2017, page 96 *

Also Published As

Publication number Publication date
JP2023107892A (ja) 2023-08-03
AU2026201801A1 (en) 2026-04-02
JP2025137626A (ja) 2025-09-19
CA3078682A1 (en) 2019-06-20
WO2019118893A1 (en) 2019-06-20
EP3724216A1 (en) 2020-10-21
AU2024200512A1 (en) 2024-02-15
US20200354413A1 (en) 2020-11-12
US20240140999A1 (en) 2024-05-02
JP2021506814A (ja) 2021-02-22
AU2018385697A1 (en) 2020-04-30
CN112119085B (zh) 2025-04-01
AU2024200512B2 (en) 2026-01-08
CN112119085A (zh) 2020-12-22
CN120118207A (zh) 2025-06-10

Similar Documents

Publication Publication Date Title
AU2024200512B2 (en) Stabilized peptide-mediated targeted protein degradation
EP2118123B1 (en) Stabilized p53 peptides and uses thereof
AU2019218786B2 (en) Cell-permeable stapled peptide modules for cellular delivery
US12570698B2 (en) Stabilized peptides for covalent binding to target protein
EP3341008B1 (en) Peptides binding to bfl-1
US12466853B2 (en) Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
AU2021360898A1 (en) Chimeric conjugates for degradation of viral and host proteins and methods of use
CA2906775A1 (en) Bh4 stabilized peptides and uses thereof
HK40126659A (en) Stabilized peptide-mediated targeted protein degradation
US20260041753A1 (en) Respiratory syncytial virus surface glycoprotein peptides, conjugates, and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)